EICHOR
● Active Not Recruiting
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
Condition: HIV-1-infection · Sponsor: Gilead Sciences
About this study
The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen for 14 days (functional monotherapy) in people with human immunodeficiency virus type 1 (HIV-1) (PWH) with multi-drug resistance (MDR).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (75)
| Ruane Clinical Research Group Inc | Los Angeles, California, United States | — |
| Mills Clinical Research | Los Angeles, California, United States | — |
| Eisenhower Health Center at Rimrock | Palm Springs, California, United States | — |
| One Community Health | Sacramento, California, United States | — |
| Yale University; School of Medicine | New Haven, Connecticut, United States | — |
| Washington Health Institute | Washington D.C., District of Columbia, United States | — |
| Midland Florida Clinical Research Center, LLC | DeLand, Florida, United States | — |
| Gary J. Richmond, M.D., P.A. | Fort Lauderdale, Florida, United States | — |
| Midway Immunology and Research Center | Ft. Pierce, Florida, United States | — |
| Floridian Clinical Research | Hialeah, Florida, United States | — |
| AIDS Healthcare Foundation - South Beach | Miami Beach, Florida, United States | — |
| Orlando Immunology Center | Orlando, Florida, United States | — |
+ 63 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04150068